I did say 'towards' being cash positive in my defence. At this...

I did say 'towards' being cash positive in my defence. At this end of the mkt cap scale its often binary - a little partnership deal for a small to medium-sized pharma, but a massive boost to OSX could so easily appear. I have long said I consider many of my small bio-tech stocks holdings like this, call options in effect. One of my other small-cap bio-tech's, destined for a capital raise at year end, pulled a partnership out at fin year end that sets it up until 2028 arguably, but more likely forever unless management cock their other applications up.

OSX could so easily announce similar.